How much does peptide and GLP-1 therapy cost in 2026? A sourced price index

If you are trying to budget for peptide or GLP-1 therapy in 2026, the honest first answer is that the number depends less on the drug than on how you pay for it. The same active ingredient can cost four figures a month at list price and a few hundred dollars through the maker’s own cash program. Tesamorelin shows the opposite problem: the approved brand, Egrifta, is a specialty drug with cash quotes in the thousands, while products sold online under the generic name are priced on a completely different basis. This page is a sourced, date-stamped price index for the therapies across our network. Every figure links to the manufacturer page, label, price-comparison site or published analysis we took it from. To weigh these prices against the evidence for a given therapy, see whether peptide therapy is worth it.

Prices rechecked October 12, 2026. Manufacturers change list prices, self-pay programs and promotional windows on short notice, and price-comparison sites update without warning. Verify the current price with the manufacturer, pharmacy or provider before relying on any number here; treat every figure as a dated snapshot, not a quote.

The 2026 therapy price index at a glance

The table aggregates the prices we could trace to a primary or clearly named source on October 12, 2026. Where a maker publishes both a list price and a cash price, both appear, because the gap between them is often the most important fact for a cash payer. Figures we could not trace are left out. PeptideAgent’s State of Peptides report for 2026 Q3 applies a similar dated-sources-only rule to its own cost data and found that only 34 of 94 price channels, covering 12 peptides, had a dated public source and a published price.

How much does peptide therapy cost?

There is no single price for peptide therapy, because the bill is built from three parts that change from one provider to the next: the provider fee, the labs, and the length of supply you are buying. Approved drugs add a fourth part, the medication’s own list or cash price, and that is the piece the manufacturers publish.

• The provider fee. Telehealth programs often charge a flat monthly subscription. Policy Lab’s TRT cost analysis puts typical subscriptions at $150 to $250 a month and notes that a $150 plan that includes labs, medication and visits is a different deal from a $100 plan that covers only the consultation, with labs and pharmacy billed separately.
• The labs. Monitoring is a real line item. Policy Lab says lab testing, consultations and monitoring are often billed separately and are frequently left out of headline prices. For tesamorelin, the Egrifta WR maker’s own safety information says your provider will run blood tests to check IGF-1 levels during treatment (Egrifta WR), so lab costs come with the drug.
• The supply length. “A month” is not always the same amount. Lilly defines a one-month Zepbound supply as 28 days (Lilly terms), NovoCare defines a Wegovy month as one box of 4 pens or one bottle of 30 tablets (NovoCare), and the Egrifta WR label describes a package of four vials with a 28-day supply of injection supplies (Egrifta WR label). Multi-month plans can lower the monthly rate, but they also lock in the spend.

The practical rule: before you compare two monthly prices, ask each provider what is included, how many days the supply covers, and whether labs are extra.

How much does tesamorelin cost?

Tesamorelin has two very different price stories, and they should not be mixed up. The approved brand, Egrifta, is a specialty prescription drug for one labeled use, reducing excess abdominal fat in adults with HIV and lipodystrophy, and its cash price runs into the thousands of dollars per supply. Products sold online under the generic name are a separate thing with separate pricing.

What Egrifta costs. The maker does not publish a cash price on its patient site, so the public figures come from price-comparison services, and they disagree:

Drugs.com lists the older vial strengths, while SingleCare quotes Egrifta WR, the newer formulation, whose label describes a package of four vials and a 28-day supply of injection supplies (Egrifta WR label). That is part of why the quotes do not line up: they are not pricing the same package. Drugs.com notes that pricing varies by pharmacy and is subject to change, and SingleCare notes that savings vary by pharmacy.

Why most Egrifta patients do not pay those numbers. The maker runs THERA patient support, which offers a co-pay assistance program for people with commercial insurance, help finding lower out-of-pocket costs for people on government insurance, and a patient assistance program that gives qualifying patients the medicine at no cost (Egrifta WR). Eligibility rules apply, and Egrifta WR’s only labeled use is the HIV-related one above.

Why the cost keeps running. The fat reduction does not appear to outlast treatment: an HIV drug guide notes that visceral abdominal fat can return a few months after tesamorelin is stopped (Positively Aware), so the relevant number is an ongoing monthly cost, not a one-off course. For what the drug does and what the trials measured, see our tesamorelin overview.

How compounded and generic-name listings differ in structure. Tesamorelin sold online under its generic name is not Egrifta, and its price is built differently. Instead of a pharmacy price for a labeled package, these listings are typically priced per multi-dose vial, described by concentration and volume, and at least one storefront we track prices its tesamorelin vial as a one-month plan with a lower per-month rate on a three-month plan. Some sellers route checkout through a medical intake, so the price may fold in a provider review; others sell vials labeled for research use with no clinician involved. Two listings with the same name can therefore differ in amount, form and what the price includes, which makes them hard to compare with each other and impossible to compare directly with Egrifta. For how online prescribing of peptides works, see our sister site’s guide to getting peptides prescribed in 2026.

How much does GLP-1 therapy cost per month without insurance?

Without insurance, branded GLP-1 medicines carry list prices around or above $1,000 a month, but few cash payers pay list anymore, because the makers now run their own self-pay programs at a fraction of it.

On the semaglutide side, Novo Nordisk lists Wegovy at $1,349.02 per package. Its Ozempic list-price page showed $1,027.51 per pen when we rechecked on October 12, 2026, with a second figure of $997.58 for the same pens on the same page, which suggests the list price is in the middle of changing; check the page before you rely on either. List price is the price set before discounts or rebates, and NovoCare notes that most people with insurance do not pay it.

On the tirzepatide side, Eli Lilly markets Zepbound for chronic weight management and Mounjaro for type 2 diabetes. Lilly’s cash access is built around Zepbound, sold as single-dose vials or a KwikPen through its Self Pay Journey Program (Lilly terms).

The takeaway for a cash payer: the self-pay programs below matter more than the list price. Our metabolic spoke walks through the cash-payer math in its guide to GLP-1 cost without insurance, and covers the investigational drug retatrutide, which has no approved price at all, in what retatrutide costs.

What is the NovoCare Wegovy (and Ozempic) self-pay price?

NovoCare is Novo Nordisk’s cash-pay pharmacy, and it prices well below list. For the Wegovy pen, NovoCare charges patients new to the program $199 for each of the first two monthly fills of the 0.25 mg and 0.5 mg starting doses through December 31, 2026, then $349 a month for the standard doses (0.25 mg through 2.4 mg) and $399 a month for Wegovy HD, the 7.2 mg dose. The Wegovy pill is cheaper still: $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg, per NovoCare’s Wegovy price guide.

Ozempic follows the same pattern: $199 for the first two monthly fills of the 0.25 mg and 0.5 mg pens through December 31, 2026, then $349 a month for 0.25 mg to 1 mg and $499 a month for 2 mg; the Ozempic pill starts at $149 a month. For people with commercial insurance, NovoCare’s savings offers let eligible patients pay as little as $25 a month for up to 3 months, capped at $100 of savings a month (NovoCare); the Wegovy offer excludes government beneficiaries (Wegovy price guide). Novo Nordisk says it can change or cancel any of these offers at any time.

The backdrop: after the FDA declared the semaglutide shortage resolved in February 2025, its grace period for compounded copies ended in 2025 (FDA). Modern Weight Medicine covers that shift in its branded versus compounded GLP-1 guide.

What is the LillyDirect Zepbound self-pay price?

LillyDirect is Eli Lilly’s direct-to-patient channel. Under its current Self Pay Journey Program terms, Zepbound costs $299 a month for 2.5 mg, $399 a month for 5 mg, and $449 a month for each of the 7.5, 10, 12.5 and 15 mg doses, whether you choose single-dose vials or the KwikPen. A one-month supply is 28 days.

The condition that changes the real cost: to keep the $449 price on the higher doses, you must complete each refill within 45 days of receiving the previous one. Miss the window and the regular price applies, which Lilly lists as $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg. Lilly’s December 2025 announcement introduced the $299, $399 and $449 vial prices; the terms page is the more recent reference, and under it the KwikPen costs the same as the vials. To compare the two main GLP-1 drugs before choosing, see semaglutide versus tirzepatide.

How much does TRT cost through telehealth?

Testosterone therapy is priced differently from GLP-1 drugs, because there is no single maker cash program; telehealth clinics bundle medication, visits and lab orders into a subscription instead. Policy Lab puts the flat monthly fee at often $150 to $250, and the overall range at about $40 to more than $1,000 a month depending on delivery method, provider model and insurance, or roughly $500 to $12,000 or more a year once labs, consultations and monitoring are counted.

Delivery method drives most of the spread. Policy Lab describes generic testosterone injections as typically the most affordable option, brand-name gels as more expensive, and implanted pellets as costing about $800 to $1,200 per insertion. Because these are market ranges rather than a published manufacturer price, ask any clinic for an itemized list of what the monthly fee covers. TRT Clarity breaks the numbers down further in its TRT cost guide.

Why isn’t there a standard price for compounded or research peptides?

Because there is no manufacturer setting one. The peptides that dominate online conversation, BPC-157, TB-500, MOTS-C, epitalon, semax, KPV and DSIP, are not FDA-approved drugs, so there is no list price, no official self-pay program and no insurer formulary to anchor a number. Prices are set by individual sellers for different forms (injectable vials, oral capsules, nasal sprays, premixed blends), different amounts per vial and different supply lengths, which makes two listings hard to compare even when the name is the same. Blends add another layer: a premixed vial of two peptides cannot be priced against either peptide alone unless you know how much of each it contains.

Price is also a weak signal of quality here. Products sold “research use only” are, by their own labeling, not intended for human use and carry no requirement for sterility validation, dose standardization or medical oversight, so a cheaper vial and a pricier one are not two points on the same quality curve. That is why we do not publish a single price range for these peptides. If you are comparing listings, the more useful questions are what form and amount you are getting, whether there is independent testing, and how long the supply lasts, which our sister publication covers in what to ask before you buy any peptide.

What do users say they pay for peptides?

The community posts our tracker has collected talk about cost a lot, but almost never in comparable dollar figures, so we cannot report a typical amount users pay. What they do report is how cost shapes their choices. Across 17 X posts on CJC-1295 (July 13 to 19, 2026) and 16 X posts on ipamorelin (July 15 to 16, 2026):

• Tesamorelin vs CJC-1295. Users comparing the two growth-hormone-releasing peptides split along cost and tolerability: some prefer CJC-1295 on cost, others tesamorelin on tolerability, and one said CJC-1295 won on cost but disrupted their sleep in a way tesamorelin did not (CJC-1295 community page).
• Fewer injections, lower spend. Some users favor the long-acting DAC form of CJC-1295 partly for less frequent injections and lower cost, while others raise concerns about it keeping growth hormone elevated continuously (CJC-1295 community page).
• Worth the money? In the ipamorelin threads, commenters group it with tesamorelin, CJC-1295, sermorelin and MK-677 when weighing which compounds are worth the cost (ipamorelin community page).

These are self-reports from one platform over short windows, not evidence of benefit, safety or typical spend. The pattern is still useful: for users, price is weighed against tolerability and convenience, not just the sticker number.

Tesamorelin vs GLP-1s vs TRT: how the price structures compare

Sources: NovoCare, Lilly terms, Policy Lab, Egrifta WR.

Why does the same drug cost so differently depending on how you pay?

The same molecule can carry several very different numbers. The list price is the maker’s published sticker price, set high and rarely paid in full by anyone with coverage. The self-pay price is the maker’s deliberate discount for people paying cash, which is why NovoCare Wegovy at $349 a month and its $1,349.02 list price are both real prices for the same drug. The insured copay is another number entirely, set by your plan’s formulary and any manufacturer savings card. And for a specialty drug like Egrifta, discount-card and pharmacy quotes can differ by thousands of dollars for what looks like the same product, as the tesamorelin table above shows.

For a cash payer, the order that usually matters is: check the maker’s official self-pay program first, because in 2026 it is often the lowest price for the branded product. That is a reversal from a couple of years ago, when compounded copies were the cheap route for GLP-1s; with that route narrowed, the makers’ own cash programs became the value option.

How to use this index without getting burned

Three habits keep you safe with any therapy price in 2026. First, treat every number as dated, including ours: the self-pay programs above carry end dates and modification rights, and one list-price page we checked showed two prices at once. Second, verify the live price at the source before you act; each row links to the page it came from. Third, be most skeptical of prices quoted most confidently for products with no maker or standard price, which is the research-peptide category above.

We recheck this page when a maker changes a list or self-pay price, when a self-pay window expires, and when a new public price source appears for a therapy we cover.

Status: It differs by substance. Our peptide status explainer gives one dated, plain-English line for each peptide named on this page.

Educational information only, not medical or financial advice. Every price on this page was rechecked on October 12, 2026 and links to its source; prices change frequently, and you should verify the current figure with the manufacturer, pharmacy or provider before relying on it.